K-Lor

Quick links to important sections

K-Lor

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of K-Lor

Quick Facts

Feature Detail
Active Ingredient Potassium chloride
Drug Class Electrolyte replenisher/Mineral
Primary Use Treat or prevent hypokalemia (low potassium)
Formulations Powder for oral solution

K-Lor Overview

K-Lor is a brand name for an oral medication containing potassium chloride (KCl), which is an electrolyte replenisher. Potassium is the primary ion found inside the body’s cells and is essential for maintaining a wide range of physiological functions, including the electrical activity of the heart, nerve impulse transmission, and muscle contraction.

Medical Uses

K-Lor is primarily prescribed to treat or prevent hypokalemia, a condition characterized by abnormally low levels of potassium in the blood. Hypokalemia can occur due to various reasons, such as prolonged illness with severe vomiting or diarrhea, certain kidney disorders, or as a side effect of taking specific medications, particularly diuretics (water pills). When dietary changes alone or reducing the diuretic dose are insufficient, K-Lor is used to correct the potassium deficit and restore the electrolyte balance.

K-Lor is typically available as a powder for oral solution. It is a prescription-only medication that is taken by mouth, often dissolved in water or juice. Because potassium chloride can irritate the gastrointestinal tract, the powder form is generally designed to be dissolved and taken with meals to minimize this risk.

Regulatory References

  1. NIH DailyMed

What side effects are possible with K-Lor ?

Possible Side Effects and Safety Information

K-Lor (potassium chloride) carries essential safety information regarding the potential for both common and serious adverse reactions.


Key Adverse Reactions

The most common adverse reactions associated with oral potassium salts are typically gastrointestinal in nature. These reactions include nausea, vomiting, diarrhea, flatulence, and abdominal pain or discomfort. A rare adverse reaction that has been reported is a skin rash.

Serious and Clinically Significant Risks

Hyperkalemia (abnormally high serum potassium concentration) is the most critical risk and can be life-threatening. Hyperkalemia can lead to severe cardiovascular effects, including cardiac arrest. Symptoms that may indicate high potassium levels include muscle weakness, listlessness, tingling sensations, and changes in heartbeat. The risk of hyperkalemia is substantially increased in patients with impaired renal function (kidney disease).

Solid oral forms of potassium chloride can cause local gastrointestinal lesions, including ulceration, bleeding, obstruction, or perforation of the stomach or intestines. Immediate discontinuation of the product is required if severe vomiting, abdominal pain, swelling, or gastrointestinal bleeding (e.g., black or tarry stools) occurs.


Safety Restrictions and Contraindications

K-Lor is contraindicated in patients who already have hyperkalemia, as further potassium administration can lead to dangerous cardiac complications. It must also not be used concomitantly with potassium-sparing diuretics (such as spironolactone, triamterene, or amiloride) due to the high risk of severe hyperkalemia.

Safety requires careful and frequent monitoring of serum potassium levels, particularly for patients with conditions that impair potassium excretion, such as chronic renal disease. Patients with delayed gastrointestinal transit due to structural, pathological, or pharmacological causes should not take solid oral dosage forms, as prolonged contact increases the risk of serious gastrointestinal lesions.

Overdose and Emergency Response

Overdose and when to seek help

The primary and most severe risk associated with an overdose of K-Lor (potassium chloride) is hyperkalemia (dangerously high blood potassium levels). This condition can be life-threatening and, in its early stages, may be asymptomatic.

Overdose risk is significantly increased in patients with pre-existing conditions that impair potassium excretion, such as chronic renal failure, systemic acidosis (e.g., diabetic acidosis), and acute dehydration.

Documented Overdose Manifestations

Official regulatory documents describe hyperkalemia presenting in stages:

  • Early Manifestations: Increased serum potassium concentration (typically 6.5 to 8.0 mEq/L) and specific changes on an electrocardiogram ( ECG), including peaking of T-waves, loss of the P-wave, and prolongation of the QT interval.
  • Late Manifestations: Severe hyperkalemia (typically 9 to 12 mEq/L) can lead to muscle paralysis and cardiovascular collapse resulting in cardiac arrest.

Emergency Response

Immediate medical help is required because potentially fatal hyperkalemia can develop rapidly. The most severe adverse effect is cardiac arrest, which can be a direct result of high potassium levels.

Treatment procedures explicitly stated in official labeling involve immediate discontinuation of the drug and institution of measures to reduce serum potassium, such as intravenous administration of calcium gluconate, sodium bicarbonate, glucose with insulin, or, if necessary, the use of exchange resins, hemodialysis, or peritoneal dialysis.

Therapeutic Uses of K-Lor

What K-Lor Treats: Main Uses and Benefits

K-Lor is primarily used for the treatment and prophylaxis of hypokalemia, which is a condition involving systemic imbalance. The medication is commonly applied in scenarios where conditions such as metabolic alkalosis or significant systemic imbalance contribute to the deficiency. It provides the necessary mineral replenishment and assists with maintaining functional stability.

It is relevant for addressing the cluster of symptoms related to physical discomfort; this helps with pronounced skeletal muscle weakness, persistent fatigue, painful muscle cramps, and symptoms related to heightened physiological activity like irregular heartbeats (arrhythmias). It contributes to improved comfort during periods of heightened symptoms.

This medication is often utilized in contexts where low potassium may affect heart function, supporting the patient during difficult episodes by easing distress. It is commonly used when conditions marked by increased physiological stress or conditions involving episodic or fluctuating manifestations are present.


Quick Fact: Relief for Muscular and Cardiac Symptoms
Primary Indication: Treatment and prevention of low blood potassium (hypokalemia).
Symptom Relief Focus: Easing symptoms related to muscle weakness and cramping, fatigue, and functional issues like irregular heartbeats linked to the deficiency.
Therapeutic Benefit: Provides support that helps ease the overall symptom burden and assists with maintaining general functional stability.

Regulatory References

  1. U.S. National Library of Medicine’s DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use K-Lor?

Eligibility for K-Lor (potassium chloride) is determined by regulatory bodies based primarily on the risk of hyperkalemia and potential gastrointestinal injury.

Contraindicated Populations

Use of K-Lor is absolutely contraindicated (must not be used) in patients with hyperkalemia (high potassium levels) and in those taking potassium-sparing diuretics (such as triamterene or amiloride).

It is also contraindicated in patients with severe renal impairment and those with conditions that cause systemic acidosis or conditions that impair potassium excretion, such as adrenal insufficiency. The use of solid forms is prohibited in patients with conditions causing delayed gastrointestinal transit, such as diabetic gastroparesis.

Age-Specific and Conditional Use

K-Lor use is established in adult and pediatric patients (birth to 16 years old). Geriatric patients are eligible, but often require careful dose selection due to a higher likelihood of decreased renal function.

Patients with impaired renal function or cirrhosis may be eligible but require extreme caution and frequent monitoring as stated in official labeling. During pregnancy and lactation, use is generally permitted if clinically needed, and is not expected to significantly affect the fetus or breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for K-Lor is primarily defined by the risk of additive hyperkalemia. Regulatory agencies formally contraindicate the co-administration of K-Lor with potassium-sparing diuretics, specifically Amiloride and Triamterene, due to the high, documented risk of severe elevation in serum potassium levels.

Pharmacodynamic and Local Interactions

A clinically significant pharmacodynamic interaction exists with numerous agents that reduce potassium excretion. These include all classes of RAAS inhibitors (such as ACE inhibitors and ARBs), Aldosterone Antagonists, and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Concurrent use with these medicines, as well as with Ciclosporin or potassium-containing salt substitutes, carries an increased potential for hyperkalemia. This interaction risk is officially documented as being heightened in patients with impaired renal function or cirrhosis.

Distinct from systemic drug interactions, the solid oral form of potassium chloride requires administration with meals and a full glass of water. This is a mandatory rule to mitigate the local interaction risk of gastrointestinal mucosal irritation. The medication is also officially noted to decrease the systemic exposure of Baloxavir Marboxil by binding cations in the digestive tract.

Mechanism of Action

How K-Lor Works: Mechanism of Action

K-Lor's mechanism is fundamentally electrolyte replenishment, directly addressing a substrate deficiency by providing potassium ions ( K^+) that are absorbed and distributed throughout the body’s fluid compartments. This action contributes to fluid and electrolyte homeostasis through potassium distribution.

The core pathway modulated is the transmembrane potential of excitable cells, including cardiac and nerve tissue. Restoration of the crucial K^+ concentration gradient influences the resting membrane potential, affecting the electrical and contractile activity associated with potassium depletion. This mechanism impacts the rate of action potential generation and propagation in excitable tissues, regulating muscle contraction and influencing the heart's electrophysiological status.

Furthermore, K-Lor provides the Cl^- counter-anion, engaging mechanisms within the renal and humoral pathways to regulate acid-base status. This anion component influences renal ion handling, affecting metabolic alkalosis by promoting renal HCO3^- excretion, which contributes to overall electrolytic balance.

Dosage and Administration Information

Instruction Map: How to use K-Lor — official administration guidelines

Administration scope

Feature Official Instruction
Route of administration Oral
Timing in relation to meals Must be taken with meals or immediately after eating to minimize potential for gastrointestinal irritation.
Missed-dose rule If a dose is missed, take it as soon as possible, unless it is almost time for the next dose. Do not double the dose to catch up.

Dosing and Preparation

Official Dosing Rules (Adults)

  • Treatment of Deficiency: Daily doses typically range from 40 to 100 mEq and must be given in 2 to 5 divided doses. Single doses should not exceed 40 mEq. The total daily dose should not exceed 200 mEq in a 24-hour period.
  • Maintenance/Prophylaxis: Typical dose is 20 mEq per day. Dosage must be individualized based on serum potassium levels.

Preparation & Special Conditions

  • Oral Solution/Powder: The solution or the contents of the powder packet must be diluted with at least 4 ounces (120 mL) of cold water before administration.
  • Extended-release Tablets: Swallow the tablets whole without crushing, chewing, or sucking to ensure the intended slow release of potassium.
  • Condition for Use: If the serum potassium concentration is determined to be less than 2.5 mEq/L, intravenous potassium should be used instead of oral supplementation.

Age-group administration rules

  • Pediatric Patients (birth to 16 years): The initial dose for treatment is 2 to 4 mEq/kg/day in divided doses. Do not exceed 1 mEq/kg as a single dose (maximum 40 mEq single dose) or a total daily dose of 100 mEq.

Connection to the overall use protocol (2–4 sentences): The official instructions mandate an oral, divided-dose protocol taken with food to ensure gradual absorption and reduce the risk of gastrointestinal irritation. The administration of K-Lor is strictly governed by maximum single and total daily doses, especially in the context of treating potassium deficiency. Crucially, the protocol requires professional monitoring of serum potassium levels and dictates that intravenous therapy is mandatory for severe deficits, highlighting the need for continuous clinical oversight.

Recent Clinical Evidence

Recent Clinical Evidence Overview

K-Lor is a brand name for potassium chloride ( KCl), an essential electrolyte used to treat and prevent hypokalemia (low blood potassium levels). Because potassium chloride is a widely available and long-established compound, clinical research focuses primarily on optimizing delivery methods, assessing safety in specific patient populations, and evaluating formulations.

Efficacy and Pharmacokinetics

Studies examining different oral formulations (liquid, powder, extended-release tablets) have focused on bioavailability—the extent to which the potassium is absorbed. Research has reported that while the rate of absorption can vary between liquid and solid formulations, the total amount of potassium absorbed over a 24-hour period is generally comparable.

  • Liquid vs. Solid Forms: Oral solutions typically show a faster initial rate of absorption compared to extended-release solid forms. However, the overall bioavailability for potassium supplementation is similar across these preparations.

Safety and Administration

The primary safety focus in clinical settings is the risk of hyperkalemia (high blood potassium), especially in patients with impaired kidney function or those taking certain interacting medications. Studies have assessed protocols for safe administration:

  • Gastrointestinal Tolerance: Research suggests that common adverse events include mild nausea, vomiting, and abdominal discomfort. Some studies indicate that solid formulations may be associated with a higher risk of gastrointestinal irritation or lesions compared to liquid forms, particularly if transit is delayed.
  • Monitoring: The use of potassium chloride in therapeutic settings requires careful, ongoing monitoring of serum potassium levels and, in some cases, Electrocardiogram (ECG) monitoring to assess the effect on cardiac rhythm.

Key Studies & References

  1. KLOR-CON - DailyMed - National Institutes of Health (NIH) Drug Label for Potassium Chloride Extended-Release Tablets

Frequently Asked Questions (FAQ)

Common questions about K-Lor (FAQ)


Q: Is it normal to have mild stomach upset after taking K-Lor?

A: Official product information states that gastrointestinal issues are among the most common adverse reactions to oral potassium salts like K-Lor. This includes experiencing nausea, vomiting, flatulence, abdominal pain, or diarrhea. Taking the medication with food, as often directed in product labeling, is intended to help reduce the potential for gastrointestinal irritation.


Q: What happens if you miss a dose of K-Lor?

A: Regulatory instructions advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory guidance states to skip the missed dose and continue with the regular schedule. It is important that the dose is not doubled to try and catch up.


Q: Can K-Lor affect your kidneys over time?

A: Official labeling does not cite K-Lor as a cause of kidney damage. However, patients with reduced kidney function may require particularly careful monitoring because of the increased risk of hyperkalemia (high potassium). Severe renal impairment is noted as a contraindication for the medication.


Q: Can K-Lor be taken with food, or should it be on an empty stomach?

A: Regulatory documents explicitly state that K-Lor must be taken with meals or immediately after eating. This official instruction is in place to help mitigate the risk of local irritation of the gastrointestinal lining. Taking the dose with a full glass of water or another liquid is also necessary for proper administration.


Q: Why are there different types of K-Lor (powder, tablet, liquid)?

A: Potassium chloride is supplied in different forms (e.g., solution, extended-release tablets) to allow for individualized administration and to manage gastrointestinal tolerance. Solid forms carry a greater risk of irritation, which is mitigated by the specialized extended-release designs. The availability of different forms allows for individualized administration based on clinical recommendation and patient tolerance of the product.


Q: Are there any common foods that interact badly with K-Lor?

A: The official product labeling specifically advises caution regarding the use of potassium-containing salt substitutes or other low-salt foods that contain potassium while using K-Lor. These products can contribute to the risk of hyperkalemia (high potassium levels). Due to this risk, the use of such substitutes is often advised to be eliminated during K-Lor treatment.


Q: Are there generic versions of K-Lor available?

A: Yes, official FDA information indicates that generic versions of the active ingredient, potassium chloride, are approved and available. These are chemically equivalent to the brand-name product.


Q: Is K-Lor used for anything besides low potassium?

A: According to the official Indications and Usage, potassium chloride is indicated only for the treatment and prevention of hypokalemia (low potassium) that may or may not be accompanied by metabolic alkalosis. It is not officially indicated for other uses.


Q: How often do people usually need blood tests while on K-Lor?

A: The necessity for blood tests depends on the therapeutic goal (e.g., treatment versus prevention). For the treatment of hypokalemia, potassium levels must be monitored frequently, often daily, until they return to the normal range. Monitoring protocols for prevention are generally less frequent, but still required, often ranging from monthly to biannually.


Q: What's the difference between K-Lor and potassium chloride sold in salt substitutes?

A: K-Lor is a regulated, prescription medication with a controlled dosage. While many salt substitutes contain potassium chloride, they are treated by regulatory labeling as substances that contribute to the overall potassium load in the body. Due to the potential for increased hyperkalemia risk when combined with K-Lor, their concurrent use requires clinical evaluation.


Q: Does K-Lor need to be taken at the exact same time every day?

A: The most important regulatory instruction is that K-Lor must be taken with a meal or immediately after a meal. Official labeling emphasizes timing around meals rather than requiring an exact, consistent clock time every day.


Q: Can K-Lor cause gas or bloating?

A: Yes, regulatory documents list common gastrointestinal adverse reactions to oral potassium salts, which include flatulence (gas) and abdominal pain/discomfort. These symptoms are often mild, and taking the medication with food as instructed is intended to help lessen irritation.


Q: Does K-Lor change the color of your urine or stool?

A: Changes to urine color are not listed as a known adverse reaction. However, a sign of a serious, though rare, side effect—gastrointestinal bleeding—is the presence of black or tarry stools. Additionally, in some extended-release solid forms, the empty wax matrix of the tablet may appear in the stool.


Q: Why do some forms of K-Lor have a waxy coating?

A: The solid forms, such as the extended-release tablets, utilize a specialized wax matrix formulation. This matrix ensures the potassium is released slowly over time, rather than all at once. This slow release is critical because it minimizes the concentration of potassium at any one point in the digestive tract, thus helping to mitigate the risk of local irritation and potential damage.


Q: What is the potassium level that usually requires K-Lor?

A: K-Lor is indicated to treat or prevent hypokalemia, which is defined as serum potassium levels falling below the normal range, typically below 3.5 mEq/L. The official administration protocol mandates that if a patient's potassium level is severely low, below 2.5 mEq/L, intravenous (IV) potassium therapy must be used instead of oral K-Lor.


Q: Do you have to take K-Lor forever once you start?

A: The duration of K-Lor therapy depends on its purpose. It may be used for a short period to treat a temporary potassium deficit. However, if it is being used for prophylaxis (prevention) due to an ongoing condition, its administration may continue as long as the underlying condition requiring potassium supplementation persists.

How should K-Lor be stored and disposed of?

Storage and Disposal of K-Lor (Potassium Chloride)

K-Lor must be stored at Controlled Room Temperature, which is 20 to 25 C (68 to 77 F), with allowed temperature excursions up to 30 C (86 F). The medication must be kept protected from light and moisture in its tightly closed original container. Liquid and solution forms must be protected from freezing.

All forms of K-Lor must be stored out of the sight and reach of children and pets.

Stability and Disposal

Solutions prepared by dissolving the powder must be used immediately after mixing and not stored for future use.

Unused or expired K-Lor should be thrown away. Patients must consult a pharmacist for guidance on proper disposal methods and should not flush the medication down a toilet or drain unless specifically instructed by regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of K-Lor  found in:

A-Z Index: